Time course of the inflammatory and oxidative stress response to pulmonary infection in mice

Matthias Lange1, Yoshimitsu Nakano, Daniel L Traber

  • 1Department of Anesthesiology, Investigational Intensive Care Unit, The University of Texas Medical Branch and Shriners Hospitals for Children, Galveston, Texas 77550, USA. lanm@gmx.de

Insights

Pulmonary infection triggers early increases in lung interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-6. These inflammatory markers peak around 9 hours, aiding understanding of infection dynamics.

Area of Science:

  • Immunology
  • Pathophysiology
  • Microbiology

Background:

  • Pulmonary infections involve inflammatory responses, including cytokine surges and nitric oxide (NO) production.
  • The precise temporal dynamics of these responses are not fully understood.
  • Pseudomonas aeruginosa is a common cause of hospital-acquired pneumonia.

Purpose of the Study:

  • To investigate the time course of proinflammatory cytokines and NO in a murine model of pulmonary infection.
  • To establish a detailed timeline of key inflammatory mediators following Pseudomonas aeruginosa challenge.

Main Methods:

  • C57BL/6 wild-type mice were infected intranasally with Pseudomonas aeruginosa.
  • Lung tissue and plasma samples were collected at 3, 6, 9, 12, and 15 hours post-infection.
  • Levels of interleukin (IL)-1β, tumor necrosis factor-alpha (TNF-α), and IL-6 were measured.

Main Results:

  • Lung IL-1β protein increased early and persisted, peaking at 9 hours post-infection.
  • Lung TNF-α and IL-6 showed less intense increases, also peaking around 9 hours.
  • Plasma IL-1β and TNF-α remained unchanged, while plasma IL-6 showed a detectable increase.

Conclusions:

  • This study defines the temporal profiles of key inflammatory cytokines in response to Pseudomonas aeruginosa lung infection.
  • Understanding these time-dependent changes offers insights into infection pathophysiology.
  • The findings may inform the timing of future therapeutic interventions for pulmonary infections.